Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  C. Abbott,et al.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein , 2017, Protoplasma.

[3]  G. Guyatt,et al.  Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis , 2017, British Medical Journal.

[4]  D. Watson,et al.  From blood to breath: New horizons for esophageal cancer biomarkers , 2016, World journal of gastroenterology.

[5]  Ji Hu,et al.  The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis. , 2016, Diabetes research and clinical practice.

[6]  Michelle D. Miller,et al.  Preliminary report of the (13)C-mixed triglyceride breath test to assess timing of pancreatic enzyme replacement therapy in children with cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  R. Yazbeck,et al.  In vitro development and validation of a non-invasive 13C-stable isotope assay for ornithine decarboxylase , 2016, Journal of breath research.

[8]  A. Tsapas,et al.  Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes , 2016, Endocrine.

[9]  L. Pani,et al.  Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[10]  A. Modak.  Regulatory issues on breath tests and updates of recent advances on [13C]-breath tests , 2013, Journal of breath research.

[11]  W. Martinet,et al.  Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis , 2013, Basic Research in Cardiology.

[12]  A. Lambeir,et al.  Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[13]  A. Scheen.  A review of gliptins in 2011 , 2012, Expert opinion on pharmacotherapy.

[14]  C. Abbott,et al.  Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis , 2011, Journal of cellular physiology.

[15]  M. Geier,et al.  Non-invasive detection of a palifermin-mediated adaptive response following chemotherapy-induced damage to the distal small intestine of rats , 2011, Cancer biology & therapy.

[16]  Sun Woo Kim,et al.  Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration , 2011, Diabetes & metabolism journal.

[17]  N. Marchionni,et al.  Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials , 2011, Diabetes/metabolism research and reviews.

[18]  C. Ahn,et al.  Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus , 2011, Diabetes & metabolism journal.

[19]  C. Deacon,et al.  Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review , 2011, Diabetes, obesity & metabolism.

[20]  J. Holst,et al.  Dipeptidyl peptidase expression during experimental colitis in mice , 2010, Inflammatory bowel diseases.

[21]  C. Abbott,et al.  Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia , 2010, Cancer biology & therapy.

[22]  C. Abbott,et al.  Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? , 2009, Trends in pharmacological sciences.

[23]  G. Davidson,et al.  13C-Sucrose Breath Test: Novel Use of a Noninvasive Biomarker of Environmental Gut Health , 2009, Pediatrics.

[24]  Xin Chen,et al.  Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. , 2009, Biochemical pharmacology.

[25]  R. Butler.  Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy of biologics including prebiotics and probiotics. , 2008, Current pharmaceutical design.

[26]  R. Butler.  Measuring tools for gastrointestinal toxicity , 2008, Current opinion in supportive and palliative care.

[27]  M. Peršić,et al.  Serum and Intestinal Dipeptidyl Peptidase IV (DPP IV/CD26) Activity in Children With Celiac Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[28]  C. Deacon.  Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes , 2007, Expert opinion on investigational drugs.

[29]  A. Woods,et al.  Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. , 2005, Diabetes.

[30]  A. Cummins,et al.  13C‐Urea breath test: Reproducibility and association with the severity of Helicobacter pylori‐associated antral gastritis , 2005, Journal of gastroenterology and hepatology.

[31]  A. Gasbarrini,et al.  Non-Invasive Assessment of Human Hepatic Mitochondrial Function through the 13C-Methionine Breath Test , 2000, Scandinavian journal of gastroenterology.

[32]  R. Haslam,et al.  Reproducibility of the 13C-octanoic acid breath test for assessment of gastric emptying in healthy preterm infants. , 1999, Journal of pediatric gastroenterology and nutrition.

[33]  D. Swallow,et al.  Regional expression of epithelial dipeptidyl peptidase IV in the human intestines. , 1994, Biochemical and biophysical research communications.

[34]  V. Ganapathy,et al.  Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. , 1993, The American journal of physiology.

[35]  D. Marguet,et al.  Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. , 1992, The Journal of biological chemistry.

[36]  M. Smith,et al.  Abnormal expression of dipeptidylpeptidase IV activity in enterocyte brush‐border membranes of children suffering from coeliac disease , 1990, Experimental Physiology.

[37]  M. Harada,et al.  Alteration in dipeptidyl peptidase activities in cultured human carcinoma cells. , 1987, Journal of the National Cancer Institute.

[38]  D. Kipnis,et al.  Alanine and glutamine synthesis and release from skeletal muscle. I. Glycolysis and amino acid release. , 1976, The Journal of biological chemistry.

[39]  C. Abbott,et al.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein , 2017, Protoplasma.

[40]  Karl H. Wolf,et al.  Comparative review , 2011, J. Documentation.

[41]  G. Glenner,et al.  A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide , 2004, Histochemie.

[42]  C. Abbott,et al.  Molecular analyses of human and rat dipeptidyl peptidase IV. , 1997, Advances in experimental medicine and biology.

[43]  G. Glenner,et al.  A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. , 1966, Histochemie. Histochemistry. Histochimie.